HUTCHMED (China) Analyst Price Targets

Wall Street analyst price targets and consensus rating for HUTCHMED (China) (HCM).

Price Target Range — 5 Quarters

Analyst Consensus — 4 Analysts

2Buy

1Hold

1Sell

Consensus RatingBuy# Analysts4Avg. Consensus PT$17Upside to Avg. PT+23.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 23, 2026	Goldman Sachs	Paul Choi	PT Cut	Neutral	$16→$14
Jul 7, 2026	B of A Securities	Alec Stranahan	PT Cut	Buy	$20→$17
Mar 10, 2026	B of A Securities	Dimple Gosai	PT Cut	Buy	$21→$20
Sep 22, 2025	Morgan Stanley	Jack Lin	Downgrade	Equal-Weight→Underweight	$18→$14
Jul 22, 2025	B of A Securities	Dimple Gosai	PT Raise	Buy	$27→$28
Aug 1, 2024	Goldman Sachs	Paul Choi	PT Raise	Neutral	$17→$19
Nov 24, 2023	Deutsche Bank	Cyrus Ng	Upgrade	Hold→Buy	$20→$22
Nov 10, 2023	Goldman Sachs	Paul Choi	PT Raise	Neutral	$15→$17

Analyst Ratings News

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and lowers the price target from $16 to $14.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17

B of A Securities analyst Alec Stranahan maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and lowers the price target from $20 to $17.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $20

B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and lowers the price target from $21 to $20.

Benzinga Newsdesk

PRO
Morgan Stanley Downgrades HUTCHMED (China) to Underweight, Lowers Price Target to $13.75

Morgan Stanley analyst Jack Lin downgrades HUTCHMED (China) (NASDAQ:HCM) from Equal-Weight to Underweight and lowers the price target from $18 to $13.75.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Raises Price Target to $28

B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and raises the price target from $27 to $28.

Benzinga Newsdesk

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $19

Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and raises the price target from $17 to $19.

Benzinga Newsdesk

HUTCHMED (China) Ltd

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

HUTCHMED (China) Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $20

PRO
Morgan Stanley Downgrades HUTCHMED (China) to Underweight, Lowers Price Target to $13.75

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Raises Price Target to $28

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $19

People Also Watch

People Also Watch

HUTCHMED (China) Ltd

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

HUTCHMED (China) Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGoldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

PROB of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17

PROB of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $20

PROMorgan Stanley Downgrades HUTCHMED (China) to Underweight, Lowers Price Target to $13.75

PROB of A Securities Maintains Buy on HUTCHMED (China), Raises Price Target to $28

PROGoldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $19

People Also Watch

People Also Watch

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $20

PRO
Morgan Stanley Downgrades HUTCHMED (China) to Underweight, Lowers Price Target to $13.75

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Raises Price Target to $28

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $19